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Abstract 
BACKGROUND & AIMS: Psoriasiform and eczematiform lesions are associated with anti-tumor necrosis 
factor (TNF)-α therapies. We assessed clinical characteristics, risk factors, and outcomes of skin disease in 
patients with inflammatory bowel diseases that presented with psoriasiform and eczematiform lesions induced by 
anti-TNF-α agents.  
METHODS: We studied 85 patients (69 with Crohn's disease, 15 with ulcerative colitis, and 1 with 
indeterminate colitis; 62 women) with inflammatory skin lesions (62 psoriasiform and 23 eczematiform lesions). 
RESULTS: Twenty-four patients had a history of inflammatory skin lesions and 15 had a familial history of 
inflammatory skin disease. Locations of eczematiform lesions varied whereas scalp and flexural varieties were 
mostly psoriasiform. Skin lesions emerged but inflammatory bowel disease was quiescent in 69 patients 
following treatment with any type of anti-TNF-α agent (60 with infliximab, 20 with adalimumab, and 5 with 
certolizumab). Topical therapy resulted in partial or total remission in 41 patients. Patients with psoriasiform 
lesions that were resistant to topical therapy and that changed anti-TNF-α therapies once or twice developed 
recurring lesions. Overall, uncontrolled skin lesions caused 29 patients to stop taking TNF-α inhibitors. 
CONCLUSIONS: Inflammatory skin lesions following therapy with TNF-α inhibitors occurred most frequently 
among women and patients with a personal or familial history of inflammatory skin disease; lesions did not 
correlate with intestinal disease activity. Recurring and intense skin lesions caused 34% of patients in this study 
to discontinue use of anti-TNF-α agents. 
Keywords : Skin Eruptions ; Dermatological Complications ; Side Effects of Anti-TNF-α Therapy. 
Abbreviations used in this paper : CD, Crohn's disease ; DLQI, Dermatology Life Quality Index ; IBD, 
inflammatory bowel disease ; IC, indeterminate colitis ; IFN, interferon ; IQR, interquartile range ; PDC, 
plasmacytoid dendritic cell ; TNF, tumor necrosis factor ; UC, ulcerative colitis ; UV, ultraviolet. 
 
Anti-tumor necrosis factor (TNF) agents are used in a wide variety of immune-mediated diseases. Their efficacy 
has been proven in the treatment of inflammatory bowel disease (IBD) including both luminal and fistulizing 
Crohn's disease (CD) and ulcerative colitis (UC).1-6 The anti-TNF agents are globally safe6 although some 
concerns have been raised regarding an increased risk of opportunistic infections7 and lymphoproliferative 
diseases8 in a small percentage of patients. Attention has recently focused on a wide spectrum of skin lesions, the 
most common being eczematiform and psoriasiform eruptions (inflammatory lesions) arising in patients treated 
with anti-TNF agents. A recent literature survey identified 127 psoriatic skin lesions induced by anti-TNF agents 
in a variety of patients,9 most of them with rheumatic disorders. These lesions appear paradoxical because TNF is 
a pivotal molecule in the physiopathology of psoriatic skin lesions and anti-TNF agents have been approved for 
treatment of moderate to severe psoriasis for 5 years.10 The risk factors and natural history of these lesions, their 
impact on the treatment of IBD, and the impact on skin disease of switching the anti-TNF are poorly 
documented. 
The aim of this study was to assess clinical characteristics, risk factors, and outcome of skin disease in a large 
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multicentric series of patients with IBD presenting with psoriasiform and eczematiform lesions induced by anti-
TNF agents (infliximab, adalimumab, and certolizumab). 
Methods  
Study Design 
We conducted a retrospective study between January 2004 and September 2009 of patients with new onset or 
exacerbation of eczematiform or psoriasiform lesions during treatment with anti-TNF agents for IBD observed in 
the GETAID centers (35 centers in Belgium, France, and Switzerland) and 1 center from Austria. Furthermore, 
from January 2006 to January 2010, all patients treated with anti-TNF agents in the department of 
hepatogastroenterology of Lille and presenting with eczematiform or psoriasiform lesions were referred to a 
single dermatologist and consecutively recorded. Eczematiform lesions were defined as the association of xerosis 
and pruriginous ill-limited plaques with etythematous or squamous macules or vesicles. Psoriasiform lesions 
were defined as well delimited scaly erythematous plaques. Nail involvement (nail pitting and nail discoloration) 
and palmoplantar pustulosis were also recorded as psoriasiform lesions. 
Data from each patient were collected using a standardized questionnaire. Patients were eligible if they 
experienced new onset, reactivation, or worsening of skin lesions (psoriasiform or eczematiform) with 
confirmation by a local dermatologist while being treated with anti-TNF agents. All cases were then reviewed 
simultaneously by a gastroenterologist JFR) and a single expert dermatologist (SB) prior to inclusion in the 
study. Histological analysis was not necessary for inclusion. Cases with imprecise dermatological diagnosis or 
absence of dermatological follow-up were excluded. 
Variables 
Clinical data included age, sex, smoking status, disease duration, IBD phenotype according to Montreal 
classification, type and dosage of the anti-TNF agent, concomitant medication, and disease activity (based on 
physician's appreciation) at the time of diagnosis of skin lesions. Information related to skin diseases included 
personal or familial (first-degree relatives) history of atopy (including atopic dermatitis, asthma, allergic rhinitis, 
and conjunctivitis) and/or psoriasis, time from starting anti-TNF agent to onset of skin lesions (the time to onset 
was considered the time the patient was regularly treated with the anti-TNF agent), morphological description, 
extent and topography of skin lesions, dermatological treatments, and histopathological information when 
available. With the Psoriasis Area and Severity Index (PASI) score being rarely applicable in our cases of 
psoriasiform lesions, the severity of the skin disease was assessed using the Dermatology Life Quality Index 
(DLQI).11 All follow-up information regarding skin complications and specific therapy was collected. Patients 
were categorized as responders or nonresponders to topical dermatological treatments. A favorable response was 
defined as a reduction of more than 50% of the lesions covering surface or a drop of the DLQI below 10. 
Persistent alteration of DLQI (above 10), withdrawal, or switching of anti-TNF agent for dermatological reasons 
was identified as nonresponse to topical treatments. Date and reason for discontinuation of anti-TNF agents 
(dermatological or nondermatological reasons), subsequent improvement of skin lesions after anti-TNF 
discontinuation, and the impact of switching the anti-TNF treatment on skin lesion outcome were also recorded. 
Results 
Description of the Population 
A total of 85 patients (23 males and 62 females) with IBD (69 CD, 15 UC, and 1 indeterminate colitis [IC]) were 
included. Demographic and clinical characteristics of patients are given in Table 1. Skin lesions were overall 
observed in patients who received infliximab (n = 60), adalimumab (n = 20), and certolizumab pegol (n = 5) 
therapy. At the time of onset of skin lesions, 79 patients were on maintenance scheduled therapy but 10 patients 
on infliximab had previous episodic treatment. No lesions occurred during high dose treatment and 6 patients 
developed skin lesions during the induction period. An estimate of the incidence of skin lesions was obtained 
from Lille Centre where, over the last 4 years, 562 patients initiated an anti-TNF treatment (341 infliximab and 
221 adalimumab). During this period, 28 patients (5%) developed an inflammatory skin lesion: 2% developed 
psoriasiform lesions, and 3% eczematiform lesions. 
 
Psoriasiform Lesions 
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Psoriasiform lesions were observed in 62 patients. None of them had psoriatic articular involvement. The median 
age at the time of occurrence of skin lesions was 32 years (interquartile range [IQR], 24 to 39) and the female to 
male ratio was 2:1. Twenty-eight were active smokers. The median time between start of anti-TNF therapy and 
the onset of psoriasiform lesions was 17 months (range, 1-60) for infliximab, 12 months for adalimumab (range, 
0.5-29), and 4.5 months for certolizumab pegol (Table 2). Fourteen patients (23%) had a previous history of 
psoriasis before treatment with any anti-TNF agent (Table 1). The others were diagnosed as a new onset of 
psoriasiform eruption (incident psoriasiform eruption). Among patients with incident psoriasiform lesions, 8 
(17%) reported a history of familial psoriasis, 2 of familial atopy, and 6 patients (13%) had personal history of 
atopy. 
 
Figure 1. (A) Psoriasiform lesions of the scalp (tinea amiantacea form) induced by infliximab. (B) Flexural 
psoriasiform lesions of the pubic region induced by infliximab. (C) Flexural psoriasiform lesions of axillae folds 
induced by adalimumab. (D) Palmo-plantar pustulosis induced by adalimumab. 
 
 
Skin lesions were distributed in single (n = 12) or multiple sites (n = 50) (Table 2). The most frequently affected 
areas were the scalp (Figure 1A) and flexures (Figure 1B and C), respectively, in 40 (64%) and 27 (43%) 
patients. Combination of scalp and flexures involvement was observed in 21 (34%) patients. Palmoplantar 
psoriasiform lesions were observed in 22 patients including palmoplantar pustulosis (Figure 1D). The well-
known "predilection" sites of psoriasis with the exception of scalp (the region sacralis and the extensor surfaces 
of the elbows and knees) were affected in 20 patients. Nail involvement was observed in 2 patients. Others 
localizations — trunk, face, members (with the exception of knees and elbows) — were observed in 11 patients. 
Distribution of skin lesions varied according to presence or absence of personal history of psoriasis. About half 
of patients with previous history of psoriasis were affected in the "predilection" sites (43%) and scalp (50%) 
whereas patients with no previous history had predominantly lesions of the scalp (69%) and flexures (46%). 
Histological data were obtained in 16 patients. Skin biopsies confirmed typical features of psoriasis, ie, 
parakeratosis, agranulosis, epidermal hyperplasia, elongation of the rete ridges, dilated capillaries in the dermis, 
and perivascular infiltration in 12 patients and a lichenoid pattern in 4 patients. No difference regarding 
distribution of psoriasiform lesions was found according to IBD type, CD and UC phenotype, disease activity, 





Table 1. Demographic, Clinical Characteristics, and Treatment of 85 Patients With Inflammatory Bowel 
Disease 
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 Psoriasiform lesions  
(n = 62) 
Eczematiform lesions  
(n = 23) 
Demographic characteristics of the population   
Male, n (%) 20 (32) 3 (13) 
Median age, y (IQR) 32 (24-39) 31 (23-39) 
Current smoker, n (%) 28 (45) 10 (43) 
Previous personal history of psoriasisa/atopyb, n (%) 14 (23)a 10 (43)b 
New onset of skin lesion, n (%) 48 (77) 13 (57) 
Personal history of atopy, n 6 - 
Personal history of psoriasis, n - 1 
Familial history of atopy, n 2 4 
Familial history of psoriasis, n 8 1 
IBD phenotype   
CD, n (%) 52 (84) 17 (74) 
UC, n (%) 9 (14) 6 (26) 
IC, n (%) 1 (2) - 
Age of diagnosis, n (%)c   
A1 15 (29) 3 (18) 
A2 34 (65) 14 (82) 
A3 3 (6) - 
Disease location, n (%)c   
L1 7 (13) 5 (30) 
L2 17 (33) 2 (11) 
L3 28 (54) 10 (59) 
L4 14 (27) 4 (24) 
Disease behavior, n (%)c   
B1 35 (67) 8 (47) 
B2 11 (21) 6 (35) 
B3 6 (12) 3 (18) 
p+ 28 (54) 8 (47) 
Extent of UC, nc   
E1 1 1 
E2 5 1 
E3 3 4 
Disease activity   
Quiescent, n (%) 49 (79) 20 (87) 
Treatment   
Anti-TNF treatment used at the time of skin lesion, n (%)   
Infliximab 45(73)d 15 (65)e 
Adalimumab 15(24)f 5 (22)g 
Certolizumab 2 (3) 3 (13) 
Use of immunomodulators at onset of skin lesion, n (%) 31 (50) 10 (43) 
Corticosteroids 5 (8) - 
Azathioprine 22 (35) 7 (30) 
Methotrexate 4 (7) 3 (13) 
No use of immunomodulators, n (%) 31 (50) 13 (57) 




cAccording to Montreal classification. 
dEight patients had episodic infliximab infusion in the past. 
eTwo patients had episodic infliximab infusion in the past. 
fEight patients received infliximab infusion in the past. 
gTwo patients received infliximab infusion in the past. 
 
 
The outcome of patients is given in Figure 2. All patients were treated with topical corticosteroids, keratolytics 
(salicylic acid, urea), emollients, and vitamin D analogues. Ultraviolet (UV) therapy (UVA or narrow band 
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UVB) was used in 10 cases and effective in 5. Of the 62 patients, 25 (40%) had a good response to topical 
treatment and 37 had no response. Presence or absence of previous personal history of psoriasis did not influence 
response to topical treatment (data not shown). Nonresponders to topical treatment were considered for 
withdrawal or switching of the anti-TNF agent. Addition of methotrexate to anti-TNF was unsuccessful in 4 
patients. First anti-TNF therapy was stopped in 18 patients (16 for dermatological reasons). Twenty-six patients 
were switched (19 for dermatological reasons and 7 for nondermatological reasons) from first anti-TNF to a 
second anti-TNF. Improvement of skin lesions was observed in only 1 patient. Recurrence of skin lesions was 
observed and easily managed in 7 patients with an initially good response to local treatment but 1 quit the anti-
TNF therapy. In 8 patients, the second anti-TNF therapy was continued despite uncontrolled skin lesions because 
the benefit/risk ratio was considered strong enough. The second anti-TNF was stopped in 7 patients allowing 
complete regression of skin lesions. Two patients were unsuccessfully switched to a third anti-TNF. Overall a 
definitive withdrawal of anti-TNF therapies due to uncontrolled skin lesion was required in 25/62 (40%) patients 
allowing a complete regression of skin lesions in 24 patients within a median time of 3 months (range, 1-10). In 
Lille Centre, a definitive withdrawal of anti-TNF therapy due to uncontrolled skin lesion was observed in 27% of 
patients with psoriasiform lesions. One patient had ongoing skin lesions 8 months after anti-TNF 
discontinuation. In patients with scalp localization, rate of abandon of the anti-TNF therapies due to uncontrolled 
skin disease was even higher approaching 48% (19/40). 
 










Table 2. Main Characteristics of the Skin Lesions Observed in 85 Patients with Inflammatory Bowel Disease 
Treated with Anti-TNF 
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 Psoriasiform lesions, 
n = 62 
Eczematiform lesions, 
n = 23 
Time between start of anti-TNF and onset of lesion   
Infliximab, mo (range) 17 (1-60) 11 (1-25) 
Adalimumab, mo (range) 12 (0.5-29) 6 (1.5-10) 
Certolizumab, mo (range) 4.5 (3-6) 14 (3-16) 
Distribution of lesions, n (%)   
Single site 12 (19) 8 (35) 
Scalp 40 (65) 6 (26) 
Flexural varieties 27 (44) 7 (30) 
Palmo plantar 22 (35) - 
Predilection sitesa 20 (32) - 
Others (trunk, members) 11 (18) 10 (43) 
Response to topic treatment   
Favorable, n (%) 25 (40) 16 (70) 
TNF, tumor necrosis factor. 
aPredilection sites (except scalp) are the region sacralis and the extensor surfaces of the elbows and knees. 
 
Eczematiform Lesions 
Eczematiform lesions were observed in 23 patients. The median age at the time of occurrence of skin lesions was 
31 years (IQR, 23-39) and the female to male ratio was 6:7. Ten patients were active smokers. The median time 
between start of anti-TNF therapy and the onset of eczematiform lesions was 11 months (range, 1-25) for 
infliximab and 6 months for adalimumab (range, 1.5-10), and 14 (range, 3-16) for certolizumab (Table 2). Of the 
23 patients who developed eczematiform lesions, 10 (44%) had a previous history of atopy (Table 1). The other 
13 patients were incident cases of atopy. Among them, 4 (31%) reported a history of familial atopy, 1 patient a 
personal history of psoriasis, and 1 of familial psoriasis. 
Eczematiform lesions were equally distributed on the scalp, trunk, members, face, and flexures (Figure 3A and 
B). There was no predominantly affected area (Table 2). Histological data were available in a minority of 
patients (n = 4), and were consistent with eczema features, ie, spongiform dermatitis with edema in the epidermis 
between keratinocytes and perivascular lymphoid infiltrate. No difference regarding topography of eczematiform 
lesions was found according to IBD type, CD, and UC phenotype, disease activity, and the anti-TNF received 
(data not shown). 
The outcome of patients is given in Figure 4. All patients were treated with topical steroids and emollients. In 1 
case, topical tacrolimus was successfully used. Of the 23 patients, 16 (70%) had a good response to topic 
treatments and 7 patients had no response (30%). Nonresponders to topic treatment were considered for 
definitive withdrawal or switching the anti-TNF agent. First anti-TNF therapy was continued in 14 patients and 
stopped in 4 patients allowing complete regression. Five patients were switched (3 for dermatological reasons) 
from the first anti-TNF to a second anti-TNF. Improvement of skin lesions was observed in only 1 patient. One 
patient was lost to follow-up. The second anti-TNF therapy was continued in 2 patients and stopped in 1. One 
patient was unsuccessfully switched to a third anti-TNF. Overall a definitive withdrawal of anti-TNF therapies 
due to an uncontrolled skin lesion was required in 4/23 patients (17%) allowing a complete regression of skin 
lesions in 3 patients (data missing for 1 patient) within a median time of 3 months (range, 1-10). In Lille Centre, 






Figure 3. (A) Eczematiform lesions of the face induced by adalimumab. (B) Nummular eczematiform lesion of 
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lower left member induced by adalimumab. 
 
 





Eczematiform and psoriasiform eruptions are, after infections, the most frequent dermatological adverse events 
in patients receiving anti-TNF-α therapy.12,13 Their prevalence in patients with IBD is unknown. Recent data 
from the rheumatologic literature indicates that the incidence rate of new onset psoriasis in patients treated with 
anti-TNF is around 1.04 (95% confidence interval, 0.97-1.54) per 1000 person-years.14 As psoriasis may be 
associated with CD,15 psoriasiform lesions may appear more frequently in this population. Fidder and colleagues 
found eczematiform or psoriasiform lesions in 9% of 743 IBD patients treated with infliximab.16 More recently, 
Esmailzadeh et al found an incidence rate of new onset eczema in 16% of patients receiving infliximab for 
various inflammatory disorders including 59 patients with IBD.17 
One strength of our series is that all cases were diagnosed by local dermatologists and centrally reviewed by 1 of 
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them (SB). We believe that this methodology avoided misclassification of psoriasiform or eczematiform lesions. 
On the other hand, it probably reflects the most severe cases of skin lesions because patients who consulted once 
and had no follow-up were considered as having minor skin lesions and excluded from the analysis. 
Skin manifestations were observed with the 3 anti-TNF agents that are used in IBD but a majority of patients 
were treated with infliximab. This most probably reflects the earlier approval of this drug in Europe. Data from 
the rheumatologic literature indicated that adalimumab induces a significantly higher rate of incident 
psoriasiform eruptions compared with etanercept or infliximab.14 Whether this is true in IBD is unknown. It is 
generally accepted that the development or worsening of psoriasiform or eczematiform lesions during treatment 
with anti-TNF therapy can occur at any time from days to years after drug initiation. We observed a median time 
of 17 months for psoriasiform lesions and 11 months for eczematiform lesions after infliximab initiation. With 
adalimumab, time to onset was slightly shorter for both types of lesions (12 months and 6 months). This shorter 
time to onset of skin lesions with adalimumab was also observed in anti-TNF naive patients. However, a wide 
range was seen in each situation, and the small number of patients developing skin lesions with adalimumab 
makes it difficult to draw a conclusion. In a large series of 120 cases in the literature the mean time to 
appearance of the psoriasiform and eczematiform lesions for all TNF-α inhibitors (infliximab, etanercept, and 
adalimumab) was 9.5 months and 4 months for adalimumab.18 
In our series, occurrence of psoriasiform or eczematiform lesions was associated with female gender and 
previous or familial history of psoriasis and/or atopy. Female predominance is well known in autoimmune 
diseases and may be related to hormonal influence and/or sex-related genes.19,20 These lesions might be gender-
related and seem to occur more frequently in women. Among patients with incident psoriasiform lesions, 17% 
had a familial history of psoriasis and 31% of patients with incident eczematiform lesions had a familial history 
of atopy. This could suggest a genetic susceptibility. Common susceptibility genes have been identified in CD 
and psoriasis.21 Ten patients (43%) with eczematiform lesions and 28 patients (45%) with psoriasiform lesions 
were smokers. Palmoplantar lesions, which can be triggered by smoking,22 were observed in 22 patients of whom 
15 (68%) were smokers. This close relationship has also been observed for other forms of psoriasis.23 
In patients with psoriasiform lesions, 2 sites were predominantly affected: the scalp and the flexures with no 
correlation with IBD phenotype, anti-TNF therapy, or disease activity. Flexural psoriasis is generally an 
uncommon phenotype affecting 2%-6% of patients with psoriasis.24 Also named inverse psoriasis, it involves the 
axillae, groins, gluteal clefts, and submammary folds but all the flexures can be affected. This phenotype which 
has already been reported in patients with CD25,26 appears less frequent in patients treated with anti-TNFs for 
rheumatologic disorders in whom the most frequent presentation is palmoplantar with or without plaque like-
psoriasis.27 
One of the most important findings is that a definitive withdrawal of anti-TNF therapies was necessary in 40% of 
patients with psoriasiform lesions and 17% with eczematiform lesions despite various therapeutic manipulations. 
Response to dermatological treatment was higher for eczematiform lesions (70%) than for psoriasiform lesions 
(40%). This poor response rate is probably biased by the severity of lesions collected in this cohort. Detailed data 
from Lille reported a definitive withdrawal of anti-TNF therapy in 27% of patients with psoriasiform lesions and 
18% of patients with eczematiform lesions. Extrapolating data from this center indicates that overall, when 
initiating anti-TNF therapies, the risk of developing an inflammatory skin lesion is around 5% and the definitive 
need to withdraw treatment due to uncontrolled skin lesion is around 1%. In the early years, switching might 
have been tempted rapidly after a failure of topical treatment. Switching from 1 TNF inhibitor to another did not 
improve psoriasiform lesions in 25/26 patients suggesting a class-related side effect. On the other hand, 
definitive resolution of skin lesions following anti-TNF discontinuation was observed in almost all patients as 
already reported.27 The effect of TNF inhibition on skin lesions is thus reversible. 
The pathogenesis of psoriasiform and eczematiform eruptions occurring under anti-TNF treatment remains 
poorly understood. They appear paradoxical because tumor necrosis factor α plays a key role in IBD and 
psoriasis28 and anti-TNF therapies can dramatically improve the outcomes of both diseases.6,28-30 Some 
hypotheses have been formulated. Plasmacytoid dendritic cells (PDCs) might play a key role in the induction of 
psoriasiform lesions by anti-TNFs.31 PDCs are natural interferon (IFN)-α producing cells. They infiltrate the skin 
of psoriatic patients and become activated to produce IFN-α early during disease formation.32 TNF inhibits PDC 
maturation from hematopoietic progenitors as well as IFN-α production.33 Subsequently, inhibition of TNF may 
allow unlimited and unregulated production of IFN-α by PDCs. Increased IFN-α expression was found in the 
dermal vasculature and in perivascular lymphocytic infiltrate of lesional skin of patients with TNF antagonist 
therapy.33 Altered lymphocyte trafficking during TNF inhibition may also participate in this process through the 
expression of chemokine receptor CXCR3 ligands.34 
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There are some limitations of this study. The main limitation concerns the selection of patients. This paper 
reports on a selected cohort of patients presenting with severe psoriasiform and eczematiform skin lesions seen 
in various centers. Thus inclusion into the study was biased by severity of skin lesions. However we believe that 
these patients with more severe skin lesions are those that pose problems to the clinicians in their daily practice. 
Therefore, the withdrawal rate, which is derived from cases at all participating centers might be biased by the 
severity of the cases collected. Secondly, our work is not an epidemiological study examining the incidence of 
skin lesions in patients with IBD treated with anti-TNF therapy. We only gave an estimate of the rate of patients 
presenting with such lesions in the Lille Centre even though this should not be seen as true incidence data. 
Lastly, the data presented are descriptive, but provide new information about increased frequency among those 
with familial/personal history of inflammatory skin lesions, an altered distribution of psoriasiform lesions in IBD 
patients not seen in the rheumatologic population, the varying distribution of lesions depending on a personal 
history of psoriasis, and the failure of resolution after switching the anti-TNF agents. 
In conclusion, psoriasiform and eczematiform skin lesions are a significant side effect of anti-TNF therapies. In 
our experience, they frequently occur in women and patients with a familial history of psoriasis and/or atopy 
lesions. Because the most severe forms can lead to cessation of anti-TNF therapy they need to be carefully 
managed with the help of a dermatologist. All patients should be referred to a dermatologist for clinical 
evaluation and biopsy of skin lesions if indicated. We recommend thorough treatment of the skin lesions by 
dermatologists with topical corticosteroids, emollients, keratolytics, vitamin D analogues, and phototherapy. 
Skin lesion resolution should be achieved in most cases. We would not advise a change in the TNF antagonists if 
the lesions are unresponsive to conventional treatment although a larger trial should address this question more 
specifically. Future research is needed to further explore epidemiological, clinical, and fundamental aspects of 
this vexing paradoxical reaction. 
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